Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Babu Gupta

Geriatric Psychiatry Cincinnati, OH Medical Doctor

NPI 1598763856 CMS profile 27149

3260 Westbourne Dr, Cincinnati, OH 45248

Open in the dashboard

General payments

$11,196

468 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$4,928 paid to institutions, not to them · program year 2025

Through program year 2025, Babu Gupta of Cincinnati, OH is reported in the CMS Open Payments database as having received $11,196 across 468 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $4,928 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 93rd percentile of Geriatric Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,356 113
2024 General $4,563 82
2023 General $1,500 84
2022 General $1,002 58
2021 General $749 49
2020 General $498 41
2019 General $530 41

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Babu Gupta
  • Geriatric Psychiatry median
  • Middle half of Geriatric Psychiatry
  • National median

In program year 2025, general payments to Babu Gupta were reported at $2,356. Among 188 Geriatric Psychiatry profiles paid that year, the median was $125 and the middle half received between $52 and $515.

Show as a table
Year Babu Gupta Geriatric Psychiatry median Middle half National median
2019 $530 $151 $47–$484 $163
2020 $498 $112 $30–$410 $114
2021 $749 $122 $35–$550 $132
2022 $1,002 $133 $54–$557 $149
2023 $1,500 $138 $61–$485 $160
2024 $4,563 $127 $51–$572 $164
2025 $2,356 $125 $52–$515 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Neuronetics, Inc. $3,344 7 payments
  2. Otsuka America Pharmaceutical, Inc. $954 59 payments
  3. Vanda Pharmaceuticals Inc. $882 40 payments
  4. Teva Pharmaceuticals USA, Inc. $880 42 payments
  5. Takeda Pharmaceuticals U.S.A., Inc. $835 70 payments
  6. E.R. Squibb & Sons, L.L.C. $595 14 payments
  7. Lundbeck LLC $522 37 payments
  8. Noven Therapeutics, LLC $457 37 payments
  9. AbbVie, Inc. $445 27 payments
  10. Alkermes, Inc. $443 28 payments
  11. Other $1,839 107 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,241 458 payments
  2. Debt forgiveness $3,256 2 payments
  3. Travel and Lodging $467 1 payment
  4. Education $233 7 payments
Products named General payments · program years 2019–2025
  1. Neurostar TMS Therapy System $3,256 2 payments
  2. FANAPT $882 40 payments
  3. HETLIOZ $813 34 payments
  4. REXULTI $803 49 payments
  5. TRINTELLIX $744 56 payments
  6. Xelstrym $457 37 payments
  7. VRAYLAR $445 27 payments
  8. Austedo XR $433 23 payments
  9. ARISTADA Cns $426 27 payments
  10. ARISTADA Cns $426 27 payments
  11. Other $4,479 290 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 59 drugs

Part D claims

5,302

Median for Psychiatry: 574

Drug cost

$560,544

Median for Psychiatry: $27,624

Branded share of claims

17.3%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Austedo Deutetrabenazine Brand 47 $347,315
Nuplazid Pimavanserin Tartrate Brand 24 $40,995
Rexulti Brexpiprazole Brand 19 $32,566
Trintellix Vortioxetine Hydrobromide Brand 37 $14,677
Duloxetine Hcl Generic 420 $13,886
Olanzapine Generic 378 $8,916
Paliperidone Er Paliperidone Brand 18 $7,827
Clozapine Generic 122 $7,630
Quetiapine Fumarate Generic 522 $7,449
Bupropion Xl Bupropion Hcl Brand 205 $6,560

The 10 drugs with the highest cost, of 59 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 24 billing codes

Paid by Medicare

$139,718

Medicare's payments for the services billed

Medicare patients

359

Average age 78

Services billed

1,949

247 women, 112 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 74%
Depression 66%
Arthritis 57%
Alzheimer's or dementia 51%
Chronic kidney disease 26%
Ischemic heart disease 25%
Diabetes 23%
Osteoporosis 23%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 20 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
REXULTI
  • Lundbeck LLC $165
  • Otsuka America Pharmaceutical, Inc. $115
$281 19 —
Xelstrym
  • Noven Therapeutics, LLC $180
$180 — —
TRINTELLIX
  • Takeda Pharmaceuticals U.S.A., Inc. $160
$160 37 —
VRAYLAR
  • AbbVie, Inc. $151
$151 — —
Austedo XR
  • Teva Pharmaceuticals USA, Inc. $100
$100 47 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 20 in the dashboard with a free account

Records

468 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Geriatric Psychiatry in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record